![ΠΡΩΤΑΘΛΗΜΑ NATIONAL LEAGUE 1 (2ος ΟΜΙΛΟΣ) Φ.Ο.ΠΡΩΤΕΑΣ ΓΡΕΒΕΝΩΝ-Α.Ο. ΑΙΟΛΟΣ ΑΓΥΙΑΣ ΠΑΤΡΩΝ 75-82 – (εικόνες) – STAR FM 933 ΠΡΩΤΑΘΛΗΜΑ NATIONAL LEAGUE 1 (2ος ΟΜΙΛΟΣ) Φ.Ο.ΠΡΩΤΕΑΣ ΓΡΕΒΕΝΩΝ-Α.Ο. ΑΙΟΛΟΣ ΑΓΥΙΑΣ ΠΑΤΡΩΝ 75-82 – (εικόνες) – STAR FM 933](https://www.star-fm.gr/wp-content/uploads/2023/10/P1010467.jpg)
ΠΡΩΤΑΘΛΗΜΑ NATIONAL LEAGUE 1 (2ος ΟΜΙΛΟΣ) Φ.Ο.ΠΡΩΤΕΑΣ ΓΡΕΒΕΝΩΝ-Α.Ο. ΑΙΟΛΟΣ ΑΓΥΙΑΣ ΠΑΤΡΩΝ 75-82 – (εικόνες) – STAR FM 933
![Upregulation of AIOLOS induces apoptosis and enhances etoposide chemosensitivity in Jurkat leukemia cells Upregulation of AIOLOS induces apoptosis and enhances etoposide chemosensitivity in Jurkat leukemia cells](https://www.spandidos-publications.com/article_images/or/33/3/OR-33-03-1319-g01.jpg)
Upregulation of AIOLOS induces apoptosis and enhances etoposide chemosensitivity in Jurkat leukemia cells
![Rate of CRL4CRBN substrate Ikaros and Aiolos degradation underlies differential activity of lenalidomide and pomalidomide in multiple myeloma cells by regulation of c-Myc and IRF4 | Blood Cancer Journal Rate of CRL4CRBN substrate Ikaros and Aiolos degradation underlies differential activity of lenalidomide and pomalidomide in multiple myeloma cells by regulation of c-Myc and IRF4 | Blood Cancer Journal](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fbcj.2015.66/MediaObjects/41408_2015_Article_BFbcj201566_Fig1_HTML.jpg)
Rate of CRL4CRBN substrate Ikaros and Aiolos degradation underlies differential activity of lenalidomide and pomalidomide in multiple myeloma cells by regulation of c-Myc and IRF4 | Blood Cancer Journal
![Aiolos represses CD4+ T cell cytotoxic programming via reciprocal regulation of TFH transcription factors and IL-2 sensitivity | Nature Communications Aiolos represses CD4+ T cell cytotoxic programming via reciprocal regulation of TFH transcription factors and IL-2 sensitivity | Nature Communications](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41467-023-37420-0/MediaObjects/41467_2023_37420_Fig1_HTML.png)
Aiolos represses CD4+ T cell cytotoxic programming via reciprocal regulation of TFH transcription factors and IL-2 sensitivity | Nature Communications
![Aiolos Bio Launches with $245 Million Series A Investment to Advance Development of Novel, Phase 2-Ready TSLP Antibody | Business Wire Aiolos Bio Launches with $245 Million Series A Investment to Advance Development of Novel, Phase 2-Ready TSLP Antibody | Business Wire](https://mms.businesswire.com/media/20231024577944/en/1922914/23/Aiolos_Bio_Logo.jpg)